Hikma PHarmaceuticals Plc annual rePort 2013 NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 16. investments in associates anD Joint ventures continueD a loss of $3 million, representing the groups share of the result of unimark remedies limited and Hubei Haosun Pharmaceutical co. ltd, isincluded in the consolidated income statement.
for the year ended 31 december 2013 for the year ended 31 december 2012 Joint Joint ventures associates total ventures associates total $m $m $m $m $m $m Balance at 1 January 38 38 37 37 additions 3 3 share of loss income 3 3 1 1 impairment of investment as explained in note 5 16 16 Balance at 31 December 3 19 22 38 38 summarised financial information in respect of the groups interests in associated companies is set out below: for the year for the year ended ended 31 december 31 december 2013 2012 $m $m total assets 226 227 total liabilities 141 119 net assets 85 108 Groups share of net assets of associates 20 26 total revenues 106 140 net loss income 14 4 Groups share of loss income of associates 3 1 the information above is adjusted for fair value adjustments arising on acquisition and to comply with the groups accounting policies.
DeferreD tax the following are the major deferred tax liabilities and assets recognised by the group and movements thereon during the current and prior reporting year.
other short-term deferred temporary amortisable fixed share-based r&d costs differences assets assets payments total $m $m $m $m $m $m at 1 January 2012 1 40 20 9 1 13 credit to income 9 1 10 At 1 January 2013 1 49 19 9 1 23 credit to income 40 1 41 acquisition of subsidiaries 4 4 At 31 December 2013 1 89 22 9 1 60 certain deferred tax assets and liabilities have been appropriately offset.
the following is the analysis of the deferred tax balances after offset forfinancial reporting purposes: as at 31 december 2013 2012 $m $m deferred tax liabilities 26 23 deferred tax assets 86 46 60 23 150
